UK Markets close in 4 hrs 32 mins

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
292.80+0.39 (+0.13%)
At close: 04:00PM EDT
292.54 -0.26 (-0.09%)
Pre-market: 04:44AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 3305.95
52-week low 3176.36
50-day moving average 3287.11
200-day moving average 3261.35

Share statistics

Avg vol (3-month) 31.37M
Avg vol (10-day) 31.49M
Shares outstanding 5254.25M
Implied shares outstanding 6N/A
Float 8255.13M
% held by insiders 10.25%
% held by institutions 194.14%
Shares short (14 Jul 2022) 43.59M
Short ratio (14 Jul 2022) 41.94
Short % of float (14 Jul 2022) 41.41%
Short % of shares outstanding (14 Jul 2022) 41.40%
Shares short (prior month 14 Jun 2022) 43.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 323 Aug 2000

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 30.84%
Operating margin (ttm)36.85%

Management effectiveness

Return on assets (ttm)13.88%
Return on equity (ttm)24.65%

Income statement

Revenue (ttm)7.95B
Revenue per share (ttm)30.97
Quarterly revenue growth (yoy)21.60%
Gross profit (ttm)3.62B
Net income avi to common (ttm)2.45B
Diluted EPS (ttm)10.49
Quarterly earnings growth (yoy)16.70%

Balance sheet

Total cash (mrq)8.24B
Total cash per share (mrq)32.21
Total debt (mrq)872.5M
Total debt/equity (mrq)8.00
Current ratio (mrq)4.75
Book value per share (mrq)34.70

Cash flow statement

Operating cash flow (ttm)2.68B
Levered free cash flow (ttm)1.88B